Anosmia
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Nielsen BioSciencesCA - San Diego
1 programCharacteristics of the Anosmic Olfactory MucosaN/A1 trial
Active Trials
Allergy TherapeuticsUK - West Sussex
1 programFirefighter s Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
2028
2029
2030
2031
Allergy TherapeuticsFirefighter s Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Nielsen BioSciencesCharacteristics of the Anosmic Olfactory Mucosa
Clinical Trials (2)
Total enrollment: 368 patients across 2 trials
NCT07867184Allergy TherapeuticsFirefighter s Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Start: Oct 2026Est. completion: Oct 2036350 patients
N/AEnrolling By Invitation
Characteristics of the Anosmic Olfactory Mucosa
Start: Nov 2023Est. completion: Oct 202418 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.